- Home
- NXGL vs OVID Comparison
NXGL vs OVID Comparison
Compare NXGL & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXGL
- OVID
- Stock Information
- Founded
- NXGL 1997
- OVID 2014
- Country
- NXGL United States
- OVID United States
- Employees
- NXGL N/A
- OVID N/A
- Industry
- NXGL Medical/Dental Instruments
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- NXGL Health Care
- OVID Health Care
- Exchange
- NXGL Nasdaq
- OVID Nasdaq
- Market Cap
- NXGL 19.7M
- OVID 20.6M
- IPO Year
- NXGL 2021
- OVID 2017
- Fundamental
- Price
- NXGL $2.43
- OVID $0.97
- Analyst Decision
- NXGL
- OVID Strong Buy
- Analyst Count
- NXGL 0
- OVID 4
- Target Price
- NXGL N/A
- OVID $3.13
- AVG Volume (30 Days)
- NXGL 65.0K
- OVID 1.7M
- Earning Date
- NXGL 08-12-2025
- OVID 08-13-2025
- Dividend Yield
- NXGL N/A
- OVID N/A
- EPS Growth
- NXGL N/A
- OVID N/A
- EPS
- NXGL N/A
- OVID N/A
- Revenue
- NXGL $11,672,000.00
- OVID $6,651,000.00
- Revenue This Year
- NXGL $52.35
- OVID N/A
- Revenue Next Year
- NXGL $42.38
- OVID $5.32
- P/E Ratio
- NXGL N/A
- OVID N/A
- Revenue Growth
- NXGL 133.02
- OVID 1070.95
- 52 Week Low
- NXGL $2.10
- OVID $0.24
- 52 Week High
- NXGL $5.10
- OVID $1.47
- Technical
- Relative Strength Index (RSI)
- NXGL 47.81
- OVID 81.75
- Support Level
- NXGL $2.21
- OVID $0.48
- Resistance Level
- NXGL $2.71
- OVID $0.87
- Average True Range (ATR)
- NXGL 0.20
- OVID 0.07
- MACD
- NXGL -0.02
- OVID 0.04
- Stochastic Oscillator
- NXGL 47.06
- OVID 90.83
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.